Tandem Diabetes Care (LTS:0M0F) Cyclically Adjusted Revenue per Share: $15.19 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
68 GF Score
Price $16.44
GF Value $29.13
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Cyclically Adjusted Revenue per Share?

Tandem Diabetes Care LTS:0M0F -2.72% 68 Cyclically Adjusted Revenue per Share is $15.19 as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $29.13 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tandem Diabetes Care's adjusted revenue per share for the three months ended in Mar. 2026 was $3.615. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $15.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tandem Diabetes Care's average Cyclically Adjusted Revenue Growth Rate was -9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tandem Diabetes Care was -5.30% per year. The lowest was -5.30% per year. And the median was -5.30% per year.

As of today (2026-07-24), Tandem Diabetes Care's current stock price is $16.44. Tandem Diabetes Care's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $15.19. Tandem Diabetes Care's Cyclically Adjusted PS Ratio of today is 1.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Tandem Diabetes Care  (LTS:0M0F) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Tandem Diabetes Care's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.44/15.19
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tandem Diabetes Care was 6.99. The lowest was 0.65. And the median was 1.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Related Terms


Tandem Diabetes Care Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 17.28 18.01 17.66 15.66

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.77 16.68 15.85 15.66 15.19

LTS:0M0F vs CNMD, AORT, LMRI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Cyclically Adjusted PS Ratio falls into.


LTS:0M0F
68GF Score
Tandem Diabetes Care Inc LTS:0M0F
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tandem Diabetes Care's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.615/330.2130*330.2130
=3.615

Current CPI (Mar. 2026) = 330.2130.

Tandem Diabetes Care Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.539 241.018 10.329
201609 4.013 241.428 5.489
201612 9.366 241.432 12.810
201703 5.951 243.801 8.060
201706 4.262 244.955 5.745
201709 5.203 246.819 6.961
201712 3.982 246.524 5.334
201803 1.516 249.554 2.006
201806 0.670 251.989 0.878
201809 0.832 252.439 1.088
201812 1.324 251.233 1.740
201903 1.142 254.202 1.483
201906 1.602 256.143 2.065
201909 1.599 256.759 2.056
201912 1.830 256.974 2.352
202003 1.639 258.115 2.097
202006 1.808 257.797 2.316
202009 2.009 260.280 2.549
202012 2.700 260.474 3.423
202103 2.258 264.877 2.815
202106 2.622 271.696 3.187
202109 2.773 274.310 3.338
202112 3.241 278.802 3.839
202203 2.754 287.504 3.163
202206 3.125 296.311 3.483
202209 3.184 296.808 3.542
202212 3.425 296.797 3.811
202303 2.624 301.836 2.871
202306 3.022 305.109 3.271
202309 2.851 307.789 3.059
202312 3.010 306.746 3.240
202403 2.934 312.332 3.102
202406 3.414 314.175 3.588
202409 3.723 315.301 3.899
202412 4.286 315.605 4.484
202503 3.530 319.799 3.645
202506 3.590 322.561 3.675
202509 3.684 324.800 3.745
202512 4.269 324.054 4.350
202603 3.615 330.213 3.615

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $15.19 mean?
Tandem Diabetes Care (LTS:0M0F) has a Cyclically Adjusted Revenue per Share of $15.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Cyclically Adjusted Revenue per Share too high?
Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is $15.19. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Cyclically Adjusted Revenue per Share compare to CNMD and AORT?
Tandem Diabetes Care's Cyclically Adjusted Revenue per Share of $15.19 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Cyclically Adjusted Revenue per Share is $15.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.13, compared to a current price of $16.44 — trading 43.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $15.19. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Cyclically Adjusted Revenue per Share is $15.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $16.44 is trading 43.6% below its estimated GF Value™ of $29.13. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Cyclically Adjusted Revenue per Share: $15.19
  • GF Value™: $29.13 vs. price of $16.44 (43.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score

Get the complete analysis for LTS:0M0F

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.44
Price
$29.13
GF Value